Funding profile · AI drug discovery

Exonic

A three person startup with no SEC filing on record and no press release naming an investor. Here is what two data aggregators report about its seed funding, and where their numbers disagree.

$500KTotal raised, reported by two data aggregators (Seed, 2025)
$1MAlternate total reported by a third aggregator, unreconciled
0SEC Form D filings found under Exonic’s name
3Investors named by PitchBook: Y Combinator, Exitfund, Pioneer Fund

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Dated Jan 1, 2025 Accelerator / incubator Not disclosed Y Combinator PitchBook
Fall 2025 Y Combinator batch Not disclosed Y Combinator, partner Pete Koomen YC
Sep 29, 2025 Seed $500,000 (reported) Not named Tracxn
Nov 17, 2025 Seed Not disclosed in round table; $500,000 total raised per FAQ Exitfund, Pioneer Fund, Y Combinator PitchBook
Undated Total funding, alternate figure $1,000,000 headline, no round detail Not stated Extruct AI

What the filings show

No Form D notice or other SEC filing under the name Exonic, in San Francisco or otherwise matching this company, appears in EDGAR’s company search as of September 2026. The only close name match is Exonics Therapeutics, Inc., CIK 0001722820, a Delaware company that was based in Watertown, Massachusetts and filed a Form D in November 2017 and an amendment in November 2018. That company made a gene therapy for Duchenne muscular dystrophy and is unrelated to this Exonic beyond the similar name.

Absent a filing, the figures above are drawn from private market data aggregators that track company funding without disclosing their sourcing methods in full, rather than from primary securities filings, so they are labeled and weighed accordingly.

Reading the filings

  1. No Form D exists to check.Companies raising under Rule 506(b) are generally expected to file a Form D within 15 days of a first sale of securities. Nothing under Exonic’s name has been filed. That does not prove no money moved: a company can raise under Section 4(a)(2) without ever filing a Form D, or a filing can be late or missed entirely.
  2. Two aggregators agree on the amount, not the date.Tracxn and PitchBook both put total funding at $500,000, but Tracxn dates the seed round to September 29, 2025, while PitchBook’s funding table dates a seed round to November 17, 2025 and lists a separate, undated accelerator event on January 1, 2025. The gap could reflect a first close and a final close, or one figure could be wrong.
  3. A third aggregator reports double.Extruct AI headlines the company’s funding at $1 million, with no round, date or investor detail behind the number. Whether that reflects a later, unfiled raise or a data error is not something this profile can settle.
  4. The investor list has no lead.PitchBook names three investors, Y Combinator, Exitfund and Pioneer Fund, without marking any of them as lead or disclosing check sizes. No press release naming any of them was found.
  5. The accelerator and the seed round may be double counted.PitchBook logs Exonic’s Y Combinator participation as a separate “Accelerator/Incubator” deal from its seed round. Whether PitchBook’s $500,000 total includes Y Combinator’s investment or sits on top of it is not stated.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k), PMA or other clearance found under Exonic’s name. Not found
Clinical or preclinical evidence Company says it beat a benchmark in HepG2 liver cancer synthetic enhancer design in its own wet lab. No publication found. Company-stated
Platform Exonic Studio, a no code platform for combining open source biological AI models, which the company says is live. Company-stated
Customers or partners None named. Not found
Advisors Company says it is advised by the former Head of AI at Ginkgo Bioworks and the first author of the Evo model, both unnamed. Company-stated

What to watch

  • A Form D or other SEC filing under Exonic’s name.
  • A published reconciliation of the $500,000 and $1 million funding figures.
  • Confirmation, from a source other than PitchBook, of Exitfund and Pioneer Fund as investors.
  • A Series A or other named round with disclosed terms.

The Exonic story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Harmonic Discovery: Also in Drug Discovery and Delivery. A New York company using machine learning to design kinase drugs that engage several targets on purpose while avoiding the ones that cause harm
  • CellType: Also in Drug Discovery and Delivery. A two person Yale spinout that translates single cell biology into a language large models can learn, and is using that model to steer a real cancer drug's next act
  • Numerion Labs: Also in Drug Discovery and Delivery. Formerly Atomwise
  • Atlas Discovery: Also in Drug Discovery and Delivery. A three person company in San Francisco building foundation models that try to say, before a patient is dosed, whether a drug will work

Sources

  1. Public recordSEC EDGAR company search for “Exonic” (no Form D found; closest match Exonics Therapeutics, Inc., unrelated)SEC EDGAR · accessed Sep 2026
  2. IndependentExonic 2026 Company Profile: Valuation, Funding & InvestorsPitchBook · accessed Aug 10, 2026
  3. IndependentExonic – 2026 Company Profile, Team, Funding & CompetitorsTracxn · accessed Jul 2, 2026
  4. IndependentExonic Funding: $1M, Complete AnalysisExtruct AI · accessed Sep 18, 2026
  5. IndependentExonic: Unsupervised Biological AIY Combinator · accessed Sep 25, 2026
  6. CompanyExonic funding profile and company descriptionInvesting Lists · Nov 9, 2025

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. No Form D was found for this company; the figures above come from private market data aggregators. Healthcare Venture Capital Fund holds no position in Exonic. This page is not an offer to sell or a recommendation to buy any security.